Kemi Biopharmaceuticals

Kemi Biopharmaceuticals is a preclinical-stage biotechnology company focused on the development of novel therapeutics targeting chemokine receptors. The company's primary research centers on the CXCR4 and CCR5 pathways, which play critical roles in cancer metastasis, immune system regulation, and viral entry. By utilizing a proprietary platform to design high-affinity antagonists, Kemi aims to address significant unmet needs in oncology and infectious diseases. Their lead programs are currently exploring the inhibition of tumor cell migration and the prevention of HIV infection. The company is headquartered in Maryland and leverages expertise in molecular pharmacology to advance its pipeline toward clinical trials.